Neumedicines, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neumedicines.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 1
1 (20.0%)NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds
Phase 2
Completed
- Conditions
- Colostomy Stoma
- Interventions
- Drug: PlaceboBiological: NM-IL-12
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Neumedicines Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02544061
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
Phase 2
- Conditions
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Neumedicines Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02544724
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
Phase 2
- Conditions
- Mycosis FungoidesSézary SyndromeCutaneous T Cell Lymphoma (CTCL)
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Neumedicines Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02542124
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome
Phase 2
Completed
- Conditions
- Hematopoietic Syndrome Due to Acute Radiation Syndrome
- Interventions
- Drug: PlaceboBiological: HemaMax
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Neumedicines Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT02343133
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
Phase 1
Completed
- Conditions
- Hematopoietic Syndrome Due to Acute Radiation Syndrome
- Interventions
- Biological: HemaMaxDrug: Placebo
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Neumedicines Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01742221
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
News
No news found